DE2741763A1 - Substituierte 6-phenyl-1,2,4-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel - Google Patents
Substituierte 6-phenyl-1,2,4-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazine, verfahren zu ihrer herstellung und sie enthaltende arzneimittelInfo
- Publication number
- DE2741763A1 DE2741763A1 DE19772741763 DE2741763A DE2741763A1 DE 2741763 A1 DE2741763 A1 DE 2741763A1 DE 19772741763 DE19772741763 DE 19772741763 DE 2741763 A DE2741763 A DE 2741763A DE 2741763 A1 DE2741763 A1 DE 2741763A1
- Authority
- DE
- Germany
- Prior art keywords
- group
- groups
- atoms
- methyl
- triazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940126601 medicinal product Drugs 0.000 title claims description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 title description 21
- 238000004519 manufacturing process Methods 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 161
- 238000010992 reflux Methods 0.000 claims description 97
- 238000000034 method Methods 0.000 claims description 57
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 49
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 49
- 239000000463 material Substances 0.000 claims description 47
- 239000002904 solvent Substances 0.000 claims description 44
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 40
- -1 thiocarbamoyl group Chemical group 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 24
- 229910052801 chlorine Inorganic materials 0.000 claims description 22
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 21
- 125000001153 fluoro group Chemical group F* 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 229910052731 fluorine Inorganic materials 0.000 claims description 15
- 125000003277 amino group Chemical group 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 10
- 239000012876 carrier material Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 230000036772 blood pressure Effects 0.000 claims description 9
- 125000001246 bromo group Chemical group Br* 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 150000002905 orthoesters Chemical class 0.000 claims description 6
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 239000012442 inert solvent Substances 0.000 claims description 5
- 150000008065 acid anhydrides Chemical class 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 208
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 147
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 131
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 129
- 239000007787 solid Substances 0.000 description 117
- 239000000243 solution Substances 0.000 description 109
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 106
- 239000013078 crystal Substances 0.000 description 105
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 97
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 71
- 239000011541 reaction mixture Substances 0.000 description 64
- 235000019441 ethanol Nutrition 0.000 description 53
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 50
- 239000000047 product Substances 0.000 description 49
- 229960000583 acetic acid Drugs 0.000 description 42
- 238000003756 stirring Methods 0.000 description 42
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 36
- 229910052794 bromium Inorganic materials 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- XZBIXDPGRMLSTC-UHFFFAOYSA-N formohydrazide Chemical compound NNC=O XZBIXDPGRMLSTC-UHFFFAOYSA-N 0.000 description 31
- 238000002844 melting Methods 0.000 description 31
- 230000008018 melting Effects 0.000 description 31
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 30
- 239000003921 oil Substances 0.000 description 27
- 235000019198 oils Nutrition 0.000 description 27
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 25
- 239000000706 filtrate Substances 0.000 description 25
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 23
- 235000011054 acetic acid Nutrition 0.000 description 22
- 239000003208 petroleum Substances 0.000 description 21
- 238000001953 recrystallisation Methods 0.000 description 21
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000004480 active ingredient Substances 0.000 description 20
- 239000012362 glacial acetic acid Substances 0.000 description 20
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 18
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000000155 melt Substances 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 13
- 239000000391 magnesium silicate Substances 0.000 description 13
- 229910052919 magnesium silicate Inorganic materials 0.000 description 13
- 235000019792 magnesium silicate Nutrition 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 12
- 235000008504 concentrate Nutrition 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 11
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 11
- 229920002261 Corn starch Polymers 0.000 description 10
- 239000008120 corn starch Substances 0.000 description 10
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 230000035939 shock Effects 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 230000004872 arterial blood pressure Effects 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000002249 anxiolytic agent Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 5
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 5
- 239000002198 insoluble material Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- ROFVGYAMRSGUSQ-UHFFFAOYSA-N 1-(2-bromoethyl)piperazine;hydrobromide Chemical compound Br.BrCCN1CCNCC1 ROFVGYAMRSGUSQ-UHFFFAOYSA-N 0.000 description 4
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 4
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 4
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000000049 anti-anxiety effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000007958 cherry flavor Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229960005152 pentetrazol Drugs 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- SEHSCBSQNGYKBH-UHFFFAOYSA-N 2,3-dimethyl-4-oxo-4-phenylbutanoic acid Chemical compound OC(=O)C(C)C(C)C(=O)C1=CC=CC=C1 SEHSCBSQNGYKBH-UHFFFAOYSA-N 0.000 description 3
- UTCVANDFQGNDKQ-UHFFFAOYSA-N 3-chloro-6-(2-chlorophenyl)pyridazine Chemical compound N1=NC(Cl)=CC=C1C1=CC=CC=C1Cl UTCVANDFQGNDKQ-UHFFFAOYSA-N 0.000 description 3
- PQRUWFXWCNWNBF-UHFFFAOYSA-N 3-chloro-6-(3-chlorophenyl)-4-methylpyridazine Chemical compound N1=C(Cl)C(C)=CC(C=2C=C(Cl)C=CC=2)=N1 PQRUWFXWCNWNBF-UHFFFAOYSA-N 0.000 description 3
- QRFJVCQGPISREA-UHFFFAOYSA-N 3-chloro-6-(3-chlorophenyl)pyridazine Chemical compound ClC1=CC=CC(C=2N=NC(Cl)=CC=2)=C1 QRFJVCQGPISREA-UHFFFAOYSA-N 0.000 description 3
- IEIFRHAHAWOUJM-UHFFFAOYSA-N 3-chloro-6-(3-methylphenyl)pyridazine Chemical compound CC1=CC=CC(C=2N=NC(Cl)=CC=2)=C1 IEIFRHAHAWOUJM-UHFFFAOYSA-N 0.000 description 3
- ARQKIDKGCMDXKY-UHFFFAOYSA-N 3-chloro-6-(4-chlorophenyl)pyridazine Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(Cl)N=N1 ARQKIDKGCMDXKY-UHFFFAOYSA-N 0.000 description 3
- BUBRFWDEAVIFMV-UHFFFAOYSA-N 3-chloro-6-phenylpyridazine Chemical compound N1=NC(Cl)=CC=C1C1=CC=CC=C1 BUBRFWDEAVIFMV-UHFFFAOYSA-N 0.000 description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 3
- 229960004782 chlordiazepoxide Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 3
- 229960004815 meprobamate Drugs 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- YRWWFLYKKZTALE-UHFFFAOYSA-N 3-(3-chlorophenyl)-1h-pyridazin-6-one Chemical compound ClC1=CC=CC(C2=NNC(=O)C=C2)=C1 YRWWFLYKKZTALE-UHFFFAOYSA-N 0.000 description 2
- PECLXFKVDLLXHC-UHFFFAOYSA-N 3-(3-chlorophenyl)-5-methyl-1h-pyridazin-6-one Chemical compound N1C(=O)C(C)=CC(C=2C=C(Cl)C=CC=2)=N1 PECLXFKVDLLXHC-UHFFFAOYSA-N 0.000 description 2
- HDMWPYSNNUJHKG-UHFFFAOYSA-N 3-(3-chlorophenyl)-5-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)C(C)CC(C=2C=C(Cl)C=CC=2)=N1 HDMWPYSNNUJHKG-UHFFFAOYSA-N 0.000 description 2
- KXRDUNVDORZUDE-UHFFFAOYSA-N 3-(4-bromophenyl)-4-methyl-1h-pyridazin-6-one Chemical compound CC1=CC(=O)NN=C1C1=CC=C(Br)C=C1 KXRDUNVDORZUDE-UHFFFAOYSA-N 0.000 description 2
- YDLINUGLEXXXOL-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-6-chloropyridazine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(Cl)N=N1 YDLINUGLEXXXOL-UHFFFAOYSA-N 0.000 description 2
- VSJCZKWUVAOYPD-UHFFFAOYSA-N 3-chloro-6-(2-fluorophenyl)pyridazine Chemical compound FC1=CC=CC=C1C1=CC=C(Cl)N=N1 VSJCZKWUVAOYPD-UHFFFAOYSA-N 0.000 description 2
- SWHBEWAGUFMFCG-UHFFFAOYSA-N 3-chloro-6-(3-fluorophenyl)pyridazine Chemical compound FC1=CC=CC(C=2N=NC(Cl)=CC=2)=C1 SWHBEWAGUFMFCG-UHFFFAOYSA-N 0.000 description 2
- MXWVARQFOWFFLN-UHFFFAOYSA-N 3-chloro-6-(4-chlorophenyl)-4-methylpyridazine Chemical compound N1=C(Cl)C(C)=CC(C=2C=CC(Cl)=CC=2)=N1 MXWVARQFOWFFLN-UHFFFAOYSA-N 0.000 description 2
- LYFFDJDAWPESSH-UHFFFAOYSA-N 3-chloro-6-(4-fluorophenyl)pyridazine Chemical compound C1=CC(F)=CC=C1C1=CC=C(Cl)N=N1 LYFFDJDAWPESSH-UHFFFAOYSA-N 0.000 description 2
- KSGYMLDMYPAMFV-UHFFFAOYSA-N 3-phenyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=CC=CC=2)=N1 KSGYMLDMYPAMFV-UHFFFAOYSA-N 0.000 description 2
- LTEAZNXORJPLBP-UHFFFAOYSA-N 4-(3-chlorophenyl)-2-methyl-4-oxobutanoic acid Chemical compound OC(=O)C(C)CC(=O)C1=CC=CC(Cl)=C1 LTEAZNXORJPLBP-UHFFFAOYSA-N 0.000 description 2
- QRPFBMZLGJGHGD-UHFFFAOYSA-N 4-(3-chlorophenyl)-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)C1=CC=CC(Cl)=C1 QRPFBMZLGJGHGD-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010053398 Clonic convulsion Diseases 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- FCCCRBDJBTVFSJ-UHFFFAOYSA-N butanehydrazide Chemical compound CCCC(=O)NN FCCCRBDJBTVFSJ-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- DXGIRFAFSFKYCF-UHFFFAOYSA-N propanehydrazide Chemical compound CCC(=O)NN DXGIRFAFSFKYCF-UHFFFAOYSA-N 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 150000004892 pyridazines Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- WKVZMKDXJFCMMD-UVWUDEKDSA-L (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;azanide;n,3-bis(2-chloroethyl)-2-ox Chemical compound [NH2-].[NH2-].Cl[Pt+2]Cl.ClCCNP1(=O)OCCCN1CCCl.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 WKVZMKDXJFCMMD-UVWUDEKDSA-L 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical compound N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 description 1
- LLMLNAVBOAMOEE-UHFFFAOYSA-N 2,3-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1Cl LLMLNAVBOAMOEE-UHFFFAOYSA-N 0.000 description 1
- IMJCLRALWLMDCZ-UHFFFAOYSA-N 2-chloro-5-methylbenzaldehyde Chemical compound CC1=CC=C(Cl)C(C=O)=C1 IMJCLRALWLMDCZ-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- CPFSOBKNKNLDCX-UHFFFAOYSA-N 2-methyl-4-oxo-4-[3-(trifluoromethyl)phenyl]butanoic acid Chemical compound OC(=O)C(C)CC(=O)C1=CC=CC(C(F)(F)F)=C1 CPFSOBKNKNLDCX-UHFFFAOYSA-N 0.000 description 1
- OOSOCAXREAGIGA-UHFFFAOYSA-N 2-morpholin-4-ylacetonitrile Chemical compound N#CCN1CCOCC1 OOSOCAXREAGIGA-UHFFFAOYSA-N 0.000 description 1
- ZWUSBSHBFFPRNE-UHFFFAOYSA-N 3,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1Cl ZWUSBSHBFFPRNE-UHFFFAOYSA-N 0.000 description 1
- AVFCWMCIFJSTAV-UHFFFAOYSA-N 3-(2-fluorophenyl)-1h-pyridazin-6-one Chemical compound FC1=CC=CC=C1C1=NNC(=O)C=C1 AVFCWMCIFJSTAV-UHFFFAOYSA-N 0.000 description 1
- IRFOYPRPMHYJBJ-UHFFFAOYSA-N 3-(2-fluorophenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound FC1=CC=CC=C1C1=NNC(=O)CC1 IRFOYPRPMHYJBJ-UHFFFAOYSA-N 0.000 description 1
- PUWMHJMSNXPBBW-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-1h-pyridazin-6-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1=NNC(=O)C=C1 PUWMHJMSNXPBBW-UHFFFAOYSA-N 0.000 description 1
- KPAMDYJRCCQOEF-UHFFFAOYSA-N 3-(3-bromo-4-methoxyphenyl)-6-chloropyridazine Chemical compound C1=C(Br)C(OC)=CC=C1C1=CC=C(Cl)N=N1 KPAMDYJRCCQOEF-UHFFFAOYSA-N 0.000 description 1
- YAKPDVKMBXCCHT-UHFFFAOYSA-N 3-(3-chlorophenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound ClC1=CC=CC(C=2CCC(=O)NN=2)=C1 YAKPDVKMBXCCHT-UHFFFAOYSA-N 0.000 description 1
- AWEXGEKXCWHJOJ-UHFFFAOYSA-N 3-(3-fluorophenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound FC1=CC=CC(C=2CCC(=O)NN=2)=C1 AWEXGEKXCWHJOJ-UHFFFAOYSA-N 0.000 description 1
- JICNGCGGNRONMO-UHFFFAOYSA-N 3-(3-methylphenyl)-1h-pyridazin-6-one Chemical compound CC1=CC=CC(C2=NNC(=O)C=C2)=C1 JICNGCGGNRONMO-UHFFFAOYSA-N 0.000 description 1
- FXGPGOXCPDDDGY-UHFFFAOYSA-N 3-(3-nitrophenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound [O-][N+](=O)C1=CC=CC(C=2CCC(=O)NN=2)=C1 FXGPGOXCPDDDGY-UHFFFAOYSA-N 0.000 description 1
- SXDHLGDAZQDUBI-UHFFFAOYSA-N 3-(4-bromophenyl)-1h-pyridazin-6-one Chemical compound C1=CC(Br)=CC=C1C1=NNC(=O)C=C1 SXDHLGDAZQDUBI-UHFFFAOYSA-N 0.000 description 1
- CDDNLMGOLYMTSF-UHFFFAOYSA-N 3-(4-bromophenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(Br)=CC=C1C1=NNC(=O)CC1 CDDNLMGOLYMTSF-UHFFFAOYSA-N 0.000 description 1
- OGOKDAMJYJGOGG-UHFFFAOYSA-N 3-(4-bromophenyl)-6-chloro-4-methylpyridazine Chemical compound CC1=CC(Cl)=NN=C1C1=CC=C(Br)C=C1 OGOKDAMJYJGOGG-UHFFFAOYSA-N 0.000 description 1
- AIOVQWFBJVWQHC-UHFFFAOYSA-N 3-(4-bromophenyl)-6-chloropyridazine Chemical compound N1=NC(Cl)=CC=C1C1=CC=C(Br)C=C1 AIOVQWFBJVWQHC-UHFFFAOYSA-N 0.000 description 1
- HALBJPGFCUGLFM-UHFFFAOYSA-N 3-(4-chlorophenyl)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1C1=NNC(=O)C=C1 HALBJPGFCUGLFM-UHFFFAOYSA-N 0.000 description 1
- AZDWIMWFLAIPIR-UHFFFAOYSA-N 3-(4-chlorophenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1C1=NNC(=O)CC1 AZDWIMWFLAIPIR-UHFFFAOYSA-N 0.000 description 1
- FSOCFFDVGGIAAW-UHFFFAOYSA-N 3-(4-chlorophenyl)-5-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)C(C)CC(C=2C=CC(Cl)=CC=2)=N1 FSOCFFDVGGIAAW-UHFFFAOYSA-N 0.000 description 1
- SWHTYHMWPIYECQ-UHFFFAOYSA-N 3-(4-fluorophenyl)-1h-pyridazin-6-one Chemical compound C1=CC(F)=CC=C1C1=NNC(=O)C=C1 SWHTYHMWPIYECQ-UHFFFAOYSA-N 0.000 description 1
- CKONBUGAZNEEMK-UHFFFAOYSA-N 3-(4-fluorophenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(F)=CC=C1C1=NNC(=O)CC1 CKONBUGAZNEEMK-UHFFFAOYSA-N 0.000 description 1
- YPVWSHFRLJMGOB-UHFFFAOYSA-N 3-(4-methyl-6-oxo-1h-pyridazin-3-yl)benzonitrile Chemical compound CC1=CC(=O)NN=C1C1=CC=CC(C#N)=C1 YPVWSHFRLJMGOB-UHFFFAOYSA-N 0.000 description 1
- VBUOEHHFVSYXTL-UHFFFAOYSA-N 3-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)benzonitrile Chemical compound CC1CC(=O)NN=C1C1=CC=CC(C#N)=C1 VBUOEHHFVSYXTL-UHFFFAOYSA-N 0.000 description 1
- BGVKWSVCRLMBEZ-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-1h-pyridazin-6-one Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=NNC(=O)C=C1 BGVKWSVCRLMBEZ-UHFFFAOYSA-N 0.000 description 1
- RUEBHJXJLFNCNJ-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=NNC(=O)CC1 RUEBHJXJLFNCNJ-UHFFFAOYSA-N 0.000 description 1
- AAXQAIMTJOZGME-UHFFFAOYSA-N 3-(6-chloro-4-methylpyridazin-3-yl)benzonitrile Chemical compound CC1=CC(Cl)=NN=C1C1=CC=CC(C#N)=C1 AAXQAIMTJOZGME-UHFFFAOYSA-N 0.000 description 1
- NMTUHPSKJJYGML-UHFFFAOYSA-N 3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC(C=O)=C1 NMTUHPSKJJYGML-UHFFFAOYSA-N 0.000 description 1
- FSPPQXYOSZEDSZ-UHFFFAOYSA-N 3-[3-(trifluoromethyl)phenyl]pyridazine Chemical compound FC(F)(F)C1=CC=CC(C=2N=NC=CC=2)=C1 FSPPQXYOSZEDSZ-UHFFFAOYSA-N 0.000 description 1
- CKLDBWVWBAOMDE-UHFFFAOYSA-N 3-benzoyl-4-methylpentanoic acid Chemical compound OC(=O)CC(C(C)C)C(=O)C1=CC=CC=C1 CKLDBWVWBAOMDE-UHFFFAOYSA-N 0.000 description 1
- QOGXAPCVURCPLG-UHFFFAOYSA-N 3-chloro-4,5-dimethyl-6-phenylpyridazine Chemical compound N1=C(Cl)C(C)=C(C)C(C=2C=CC=CC=2)=N1 QOGXAPCVURCPLG-UHFFFAOYSA-N 0.000 description 1
- BHQLICWJGHNZMW-UHFFFAOYSA-N 3-chloro-4-(2-methylpropyl)pyridazine Chemical compound CC(C)CC1=CC=NN=C1Cl BHQLICWJGHNZMW-UHFFFAOYSA-N 0.000 description 1
- ROVPWRBPJHXFRE-UHFFFAOYSA-N 3-chloro-4-methyl-6-phenylpyridazine Chemical compound N1=C(Cl)C(C)=CC(C=2C=CC=CC=2)=N1 ROVPWRBPJHXFRE-UHFFFAOYSA-N 0.000 description 1
- NWSKKQLZBXTZTP-UHFFFAOYSA-N 3-chloro-5-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC(Cl)=CC(C=O)=C1 NWSKKQLZBXTZTP-UHFFFAOYSA-N 0.000 description 1
- MUGNVSDURCQUTP-UHFFFAOYSA-N 3-chloro-6-(2,3-dichlorophenyl)pyridazine Chemical compound N1=NC(Cl)=CC=C1C1=CC=CC(Cl)=C1Cl MUGNVSDURCQUTP-UHFFFAOYSA-N 0.000 description 1
- AZOCIGHGYQOAGO-UHFFFAOYSA-N 3-chloro-6-(2-chloro-5-methylphenyl)pyridazine Chemical compound CC1=CC=C(Cl)C(C=2N=NC(Cl)=CC=2)=C1 AZOCIGHGYQOAGO-UHFFFAOYSA-N 0.000 description 1
- MIZBDHFLBBSBFA-UHFFFAOYSA-N 3-chloro-6-(3,4-dichlorophenyl)pyridazine Chemical compound N1=NC(Cl)=CC=C1C1=CC=C(Cl)C(Cl)=C1 MIZBDHFLBBSBFA-UHFFFAOYSA-N 0.000 description 1
- RFMQVFYQCHERQJ-UHFFFAOYSA-N 3-chloro-6-(5-chloro-2-methylphenyl)pyridazine Chemical compound CC1=CC=C(Cl)C=C1C1=CC=C(Cl)N=N1 RFMQVFYQCHERQJ-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- QJQANEWATJTSOX-UHFFFAOYSA-N 3-methyl-4-(3-nitrophenyl)-4-oxobutanenitrile Chemical compound N#CCC(C)C(=O)C1=CC=CC([N+]([O-])=O)=C1 QJQANEWATJTSOX-UHFFFAOYSA-N 0.000 description 1
- PBSHUUOWSKHHSP-UHFFFAOYSA-N 3-methyl-4-(3-nitrophenyl)-4-oxobutanoic acid Chemical compound OC(=O)CC(C)C(=O)C1=CC=CC([N+]([O-])=O)=C1 PBSHUUOWSKHHSP-UHFFFAOYSA-N 0.000 description 1
- SSTCKJHRAUJYOP-UHFFFAOYSA-N 3-methyl-4-oxo-4-[3-(trifluoromethyl)phenyl]butanenitrile Chemical compound N#CCC(C)C(=O)C1=CC=CC(C(F)(F)F)=C1 SSTCKJHRAUJYOP-UHFFFAOYSA-N 0.000 description 1
- JFOBTCFBFOHZOG-UHFFFAOYSA-N 3-methyl-4-oxo-4-[3-(trifluoromethyl)phenyl]butanoic acid Chemical compound OC(=O)CC(C)C(=O)C1=CC=CC(C(F)(F)F)=C1 JFOBTCFBFOHZOG-UHFFFAOYSA-N 0.000 description 1
- YBDWBJYRJYONCB-UHFFFAOYSA-N 3-methyl-4-oxo-4-phenylbutanoic acid Chemical compound OC(=O)CC(C)C(=O)C1=CC=CC=C1 YBDWBJYRJYONCB-UHFFFAOYSA-N 0.000 description 1
- MXDRPNGTQDRKQM-UHFFFAOYSA-N 3-methylpyridazine Chemical compound CC1=CC=CN=N1 MXDRPNGTQDRKQM-UHFFFAOYSA-N 0.000 description 1
- DFATXMYLKPCSCX-UHFFFAOYSA-N 3-methylsuccinic anhydride Chemical compound CC1CC(=O)OC1=O DFATXMYLKPCSCX-UHFFFAOYSA-N 0.000 description 1
- IJUIPRDMWWBTTQ-UHFFFAOYSA-N 3-phenyl-1h-pyridazin-6-one Chemical compound N1C(=O)C=CC(C=2C=CC=CC=2)=N1 IJUIPRDMWWBTTQ-UHFFFAOYSA-N 0.000 description 1
- ORSUMIZRRGPJBR-UHFFFAOYSA-N 4,5-dihydro-1h-pyridazin-6-one Chemical compound O=C1CCC=NN1 ORSUMIZRRGPJBR-UHFFFAOYSA-N 0.000 description 1
- HMSVRNAEPAIGSD-UHFFFAOYSA-N 4,5-dimethyl-3-phenyl-1h-pyridazin-6-one Chemical compound CC1=C(C)C(=O)NN=C1C1=CC=CC=C1 HMSVRNAEPAIGSD-UHFFFAOYSA-N 0.000 description 1
- CAWSKFGFQZNQFF-UHFFFAOYSA-N 4,5-dimethyl-3-phenyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)C(C)C(C)C(C=2C=CC=CC=2)=N1 CAWSKFGFQZNQFF-UHFFFAOYSA-N 0.000 description 1
- XJFDDBGFUOYZRJ-UHFFFAOYSA-N 4-(3-chlorophenyl)-2-methyl-4-oxobutanenitrile Chemical compound N#CC(C)CC(=O)C1=CC=CC(Cl)=C1 XJFDDBGFUOYZRJ-UHFFFAOYSA-N 0.000 description 1
- MOPBGBQUTNZWPZ-UHFFFAOYSA-N 4-(3-chlorophenyl)-4-oxobutanenitrile Chemical compound ClC1=CC=CC(C(=O)CCC#N)=C1 MOPBGBQUTNZWPZ-UHFFFAOYSA-N 0.000 description 1
- RKEDBIXJVKQBMS-UHFFFAOYSA-N 4-(4-methyl-6-oxo-1h-pyridazin-3-yl)benzonitrile Chemical compound CC1=CC(=O)NN=C1C1=CC=C(C#N)C=C1 RKEDBIXJVKQBMS-UHFFFAOYSA-N 0.000 description 1
- GSENDMUBLCAYIT-UHFFFAOYSA-N 4-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)benzonitrile Chemical compound CC1CC(=O)NN=C1C1=CC=C(C#N)C=C1 GSENDMUBLCAYIT-UHFFFAOYSA-N 0.000 description 1
- XJHBTHNAMOUNRQ-UHFFFAOYSA-N 4-(4-tert-butylphenyl)-4-oxobutanoic acid Chemical compound CC(C)(C)C1=CC=C(C(=O)CCC(O)=O)C=C1 XJHBTHNAMOUNRQ-UHFFFAOYSA-N 0.000 description 1
- OBUWGALUBISALP-UHFFFAOYSA-N 4-(6-chloro-4-methylpyridazin-3-yl)benzonitrile Chemical compound CC1=CC(Cl)=NN=C1C1=CC=C(C#N)C=C1 OBUWGALUBISALP-UHFFFAOYSA-N 0.000 description 1
- HEKNIPLMGLOMOP-UHFFFAOYSA-N 4-(6-oxo-1h-pyridazin-3-yl)benzonitrile Chemical compound N1C(=O)C=CC(C=2C=CC(=CC=2)C#N)=N1 HEKNIPLMGLOMOP-UHFFFAOYSA-N 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- NIHMMULLFBKTOK-UHFFFAOYSA-N 4-chloro-3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC(C=O)=CC=C1Cl NIHMMULLFBKTOK-UHFFFAOYSA-N 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- BIUDHHGROGJSHN-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)benzaldehyde Chemical group FC1=CC=C(C=O)C=C1C(F)(F)F BIUDHHGROGJSHN-UHFFFAOYSA-N 0.000 description 1
- XTEJJWRMZPQXTO-UHFFFAOYSA-N 4-methyl-2-phenacylpentanoic acid Chemical compound CC(C)CC(C(O)=O)CC(=O)C1=CC=CC=C1 XTEJJWRMZPQXTO-UHFFFAOYSA-N 0.000 description 1
- CDDNEPVRXGLCQG-UHFFFAOYSA-N 4-methyl-3-(3-nitrophenyl)-1h-pyridazin-6-one Chemical compound CC1=CC(=O)NN=C1C1=CC=CC([N+]([O-])=O)=C1 CDDNEPVRXGLCQG-UHFFFAOYSA-N 0.000 description 1
- DQVXIICCNCTEGA-UHFFFAOYSA-N 4-methyl-3-(3-nitrophenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=CC([N+]([O-])=O)=C1 DQVXIICCNCTEGA-UHFFFAOYSA-N 0.000 description 1
- KMQLIDDEQAJAGJ-UHFFFAOYSA-N 4-oxo-4-phenylbutyric acid Chemical class OC(=O)CCC(=O)C1=CC=CC=C1 KMQLIDDEQAJAGJ-UHFFFAOYSA-N 0.000 description 1
- ASPDJZINBYYZRU-UHFFFAOYSA-N 5-amino-2-chlorobenzotrifluoride Chemical compound NC1=CC=C(Cl)C(C(F)(F)F)=C1 ASPDJZINBYYZRU-UHFFFAOYSA-N 0.000 description 1
- DDYTVUGYXUWXGN-UHFFFAOYSA-N 5-chloro-2-methylbenzaldehyde Chemical compound CC1=CC=C(Cl)C=C1C=O DDYTVUGYXUWXGN-UHFFFAOYSA-N 0.000 description 1
- HNZITGUYCFHIMD-UHFFFAOYSA-N 5-methyl-3-phenyl-1h-pyridazin-6-one Chemical compound N1C(=O)C(C)=CC(C=2C=CC=CC=2)=N1 HNZITGUYCFHIMD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 101100178983 Caenorhabditis elegans hyl-1 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000693231 Homo sapiens PDZK1-interacting protein 1 Proteins 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102100025648 PDZK1-interacting protein 1 Human genes 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QIOZLISABUUKJY-UHFFFAOYSA-N Thiobenzamide Chemical compound NC(=S)C1=CC=CC=C1 QIOZLISABUUKJY-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ZSLZEMNLILRXLF-UHFFFAOYSA-N [6-(3-chlorophenyl)pyridazin-3-yl]hydrazine Chemical compound N1=NC(NN)=CC=C1C1=CC=CC(Cl)=C1 ZSLZEMNLILRXLF-UHFFFAOYSA-N 0.000 description 1
- YBGJZYCWGNYUMA-UHFFFAOYSA-M [Cl-].[P+]=O Chemical compound [Cl-].[P+]=O YBGJZYCWGNYUMA-UHFFFAOYSA-M 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- NKKMVIVFRUYPLQ-NSCUHMNNSA-N crotononitrile Chemical compound C\C=C\C#N NKKMVIVFRUYPLQ-NSCUHMNNSA-N 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- OVWYEQOVUDKZNU-UHFFFAOYSA-N m-tolualdehyde Chemical compound CC1=CC=CC(C=O)=C1 OVWYEQOVUDKZNU-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- QULYNCCPRWKEMF-UHFFFAOYSA-N parachlorobenzotrifluoride Chemical compound FC(F)(F)C1=CC=C(Cl)C=C1 QULYNCCPRWKEMF-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- YTRGNBTVTHPFJM-UHFFFAOYSA-N pyridazin-3-ylhydrazine Chemical compound NNC1=CC=CN=N1 YTRGNBTVTHPFJM-UHFFFAOYSA-N 0.000 description 1
- WFJZBOIOPMOUCB-UHFFFAOYSA-N pyridazine;hydrochloride Chemical compound Cl.C1=CC=NN=C1 WFJZBOIOPMOUCB-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- LJRGBERXYNQPJI-UHFFFAOYSA-M sodium;3-nitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC=CC(S([O-])(=O)=O)=C1 LJRGBERXYNQPJI-UHFFFAOYSA-M 0.000 description 1
- 230000005418 spin wave Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/08—Preparation of carboxylic acids or their salts, halides or anhydrides from nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/12—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/725,597 US4230705A (en) | 1976-09-22 | 1976-09-22 | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
US73039576A | 1976-10-07 | 1976-10-07 | |
US73547576A | 1976-10-26 | 1976-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE2741763A1 true DE2741763A1 (de) | 1978-03-23 |
Family
ID=27419081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19772741763 Withdrawn DE2741763A1 (de) | 1976-09-22 | 1977-09-16 | Substituierte 6-phenyl-1,2,4-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
Country Status (19)
Country | Link |
---|---|
JP (1) | JPS5340798A (cs) |
AR (2) | AR218036A1 (cs) |
AT (1) | AT360034B (cs) |
AU (1) | AU513760B2 (cs) |
BG (1) | BG29287A3 (cs) |
CA (1) | CA1080712A (cs) |
DD (1) | DD132586A5 (cs) |
DE (1) | DE2741763A1 (cs) |
DK (1) | DK417377A (cs) |
ES (3) | ES462543A1 (cs) |
FI (1) | FI772802A7 (cs) |
FR (1) | FR2442848A1 (cs) |
GB (1) | GB1589237A (cs) |
GR (1) | GR71699B (cs) |
LU (1) | LU78150A1 (cs) |
NL (1) | NL7710389A (cs) |
NO (1) | NO773245L (cs) |
PT (1) | PT67067B (cs) |
RO (1) | RO72226A (cs) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0029130A1 (en) * | 1979-10-29 | 1981-05-27 | The Dow Chemical Company | 3,6,7,8-Substituted-s-triazolo(4,3-b)-pyridazines, their preparation and compositions comprising them |
FR2473522A1 (fr) * | 1980-01-16 | 1981-07-17 | Synthelabo | Nouveaux derives substitues de dihydro-2,3 imidazo(1,2-b)pyridazines et les medicaments, utiles notamment comme antidepresseurs, qui en contiennent |
EP0094038A1 (de) * | 1982-05-08 | 1983-11-16 | Hoechst Aktiengesellschaft | 3-Amino-6-aryl-1,2,4-triazolo(4,3-b)-pyridazine, ihre Herstellung und ihre Verwendung |
US4487930A (en) * | 1982-09-07 | 1984-12-11 | The Dow Chemical Company | 6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines |
US4767765A (en) * | 1985-10-31 | 1988-08-30 | American Cyanamid Company | N-substituted-N-[3-(1,2,4-triazolo-[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
US4810705A (en) * | 1984-03-03 | 1989-03-07 | Sanofi | Triazolo [3,4-b]pyridazines, process for their preparation and pharmaceutical compositions containing them |
WO1999036423A1 (en) * | 1998-01-14 | 1999-07-22 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for gaba receptors |
WO1999037644A1 (en) * | 1998-01-21 | 1999-07-29 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for gaba receptors |
WO1999037645A1 (en) * | 1998-01-21 | 1999-07-29 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for gaba receptors |
WO1999037646A1 (en) * | 1998-01-21 | 1999-07-29 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for gaba receptors |
US6255305B1 (en) | 1996-07-25 | 2001-07-03 | Merck Sharp & Dohme Limited | Substituted triazolo-pyridazine derivatives as ligands for GABA receptors |
US6291460B1 (en) | 1998-01-22 | 2001-09-18 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for GABA receptors |
US6303605B1 (en) | 1998-01-21 | 2001-10-16 | Merck Sharp & Dohme Ltd. | Triazolo-pyridazine derivatives as ligands for GABA receptors |
US6319924B1 (en) | 1998-01-21 | 2001-11-20 | Merck Sharp & Dohme Ltd. | Triazolo-pyridazine derivatives as ligands for GABA receptors |
US6399608B1 (en) | 1998-01-23 | 2002-06-04 | Merck Sharp & Dohme Ltd. | Combination of a GABA-A α 2/3 agonist and a selective serotonin reuptake inhibitor |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0036711B1 (en) * | 1980-03-22 | 1985-12-04 | Fbc Limited | Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use |
US4654343A (en) * | 1985-10-31 | 1987-03-31 | American Cyanamid Company | N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
WO2005077953A1 (ja) * | 2004-02-18 | 2005-08-25 | Banyu Pharmaceutical Co., Ltd. | 含窒素縮合へテロ芳香環誘導体 |
PT3548033T (pt) * | 2016-11-28 | 2024-08-09 | Praxis Prec Medicines Inc | Compostos e respectivos métodos de utilização |
CA3101324A1 (en) | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
WO2021126779A1 (en) * | 2019-12-18 | 2021-06-24 | The Regents Of The University Of California | Inhibitors of lin28 and methods of use thereof |
-
1977
- 1977-08-16 CA CA284,806A patent/CA1080712A/en not_active Expired
- 1977-08-19 GR GR54197A patent/GR71699B/el unknown
- 1977-09-07 AR AR269126A patent/AR218036A1/es active
- 1977-09-16 DE DE19772741763 patent/DE2741763A1/de not_active Withdrawn
- 1977-09-20 LU LU78150A patent/LU78150A1/xx unknown
- 1977-09-20 RO RO7791618A patent/RO72226A/ro unknown
- 1977-09-20 BG BG037371A patent/BG29287A3/xx unknown
- 1977-09-21 AT AT677577A patent/AT360034B/de not_active IP Right Cessation
- 1977-09-21 DK DK417377A patent/DK417377A/da unknown
- 1977-09-21 AU AU28995/77A patent/AU513760B2/en not_active Expired
- 1977-09-21 NO NO773245A patent/NO773245L/no unknown
- 1977-09-22 ES ES462543A patent/ES462543A1/es not_active Expired
- 1977-09-22 NL NL7710389A patent/NL7710389A/xx not_active Application Discontinuation
- 1977-09-22 FR FR7728639A patent/FR2442848A1/fr active Pending
- 1977-09-22 FI FI772802A patent/FI772802A7/fi not_active Application Discontinuation
- 1977-09-22 DD DD7700201157A patent/DD132586A5/xx unknown
- 1977-09-22 PT PT67067A patent/PT67067B/pt unknown
- 1977-09-22 GB GB39619/77A patent/GB1589237A/en not_active Expired
- 1977-09-22 JP JP11344877A patent/JPS5340798A/ja active Pending
-
1978
- 1978-12-18 AR AR274489A patent/AR217886A1/es active
-
1979
- 1979-02-16 ES ES477799A patent/ES477799A1/es not_active Expired
- 1979-02-16 ES ES477800A patent/ES477800A1/es not_active Expired
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0029130A1 (en) * | 1979-10-29 | 1981-05-27 | The Dow Chemical Company | 3,6,7,8-Substituted-s-triazolo(4,3-b)-pyridazines, their preparation and compositions comprising them |
FR2473522A1 (fr) * | 1980-01-16 | 1981-07-17 | Synthelabo | Nouveaux derives substitues de dihydro-2,3 imidazo(1,2-b)pyridazines et les medicaments, utiles notamment comme antidepresseurs, qui en contiennent |
EP0032856A1 (fr) * | 1980-01-16 | 1981-07-29 | Synthelabo | Nouveaux dérivés de dihydro-2,3-imidazo(1,2-b)pyridazines, leur procédé de préparation et leur application en thérapeutique |
EP0094038A1 (de) * | 1982-05-08 | 1983-11-16 | Hoechst Aktiengesellschaft | 3-Amino-6-aryl-1,2,4-triazolo(4,3-b)-pyridazine, ihre Herstellung und ihre Verwendung |
US4487930A (en) * | 1982-09-07 | 1984-12-11 | The Dow Chemical Company | 6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines |
US4810705A (en) * | 1984-03-03 | 1989-03-07 | Sanofi | Triazolo [3,4-b]pyridazines, process for their preparation and pharmaceutical compositions containing them |
US4767765A (en) * | 1985-10-31 | 1988-08-30 | American Cyanamid Company | N-substituted-N-[3-(1,2,4-triazolo-[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
US6255305B1 (en) | 1996-07-25 | 2001-07-03 | Merck Sharp & Dohme Limited | Substituted triazolo-pyridazine derivatives as ligands for GABA receptors |
EA002436B1 (ru) * | 1996-07-25 | 2002-04-25 | Мерк Шарп Энд Домэ Лимитед | Замещенные производные триазоло-пиридазина в качестве лигандов рецепторов гамк |
WO1999036423A1 (en) * | 1998-01-14 | 1999-07-22 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for gaba receptors |
US6303597B1 (en) | 1998-01-14 | 2001-10-16 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for GABA receptors |
WO1999037646A1 (en) * | 1998-01-21 | 1999-07-29 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for gaba receptors |
WO1999037645A1 (en) * | 1998-01-21 | 1999-07-29 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for gaba receptors |
US6303605B1 (en) | 1998-01-21 | 2001-10-16 | Merck Sharp & Dohme Ltd. | Triazolo-pyridazine derivatives as ligands for GABA receptors |
US6319924B1 (en) | 1998-01-21 | 2001-11-20 | Merck Sharp & Dohme Ltd. | Triazolo-pyridazine derivatives as ligands for GABA receptors |
US6355798B1 (en) | 1998-01-21 | 2002-03-12 | Merck Sharp & Dohme Ltd. | Triazolo-pyridazine derivatives as ligands for GABA receptors |
WO1999037644A1 (en) * | 1998-01-21 | 1999-07-29 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for gaba receptors |
US6579875B1 (en) | 1998-01-21 | 2003-06-17 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for GABA receptors |
US6699859B1 (en) | 1998-01-21 | 2004-03-02 | Merck Sharp & Dohme Ltd. | Triazolo-pyridazine derivatives as ligands for GABA receptors |
US6828322B2 (en) | 1998-01-21 | 2004-12-07 | Merck Sharp & Dohme Ltd. | Triazolo-pyridazine derivatives as ligands for GABA receptors |
US6291460B1 (en) | 1998-01-22 | 2001-09-18 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for GABA receptors |
US6399608B1 (en) | 1998-01-23 | 2002-06-04 | Merck Sharp & Dohme Ltd. | Combination of a GABA-A α 2/3 agonist and a selective serotonin reuptake inhibitor |
Also Published As
Publication number | Publication date |
---|---|
BG29287A3 (bg) | 1980-10-15 |
GR71699B (cs) | 1983-06-21 |
PT67067A (en) | 1977-10-01 |
RO72226A (ro) | 1982-09-09 |
AU513760B2 (en) | 1980-12-18 |
AU2899577A (en) | 1979-03-29 |
AR217886A1 (es) | 1980-04-30 |
LU78150A1 (cs) | 1978-01-23 |
CA1080712A (en) | 1980-07-01 |
DD132586A5 (de) | 1978-10-11 |
NO773245L (no) | 1978-03-28 |
DK417377A (da) | 1978-03-23 |
JPS5340798A (en) | 1978-04-13 |
GB1589237A (en) | 1981-05-07 |
ES477799A1 (es) | 1980-04-01 |
FR2442848A1 (fr) | 1980-06-27 |
ES462543A1 (es) | 1979-06-16 |
PT67067B (en) | 1979-02-19 |
ES477800A1 (es) | 1979-10-16 |
FI772802A7 (fi) | 1978-03-23 |
ATA677577A (de) | 1980-05-15 |
AR218036A1 (es) | 1980-05-15 |
AT360034B (de) | 1980-12-10 |
NL7710389A (nl) | 1978-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2741763A1 (de) | Substituierte 6-phenyl-1,2,4-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
US4112095A (en) | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents | |
DE69822172T2 (de) | Levosimendanhaltige oral anzuwendende arzneizusammensetzungen | |
EP0148440B1 (de) | 1,3,4,5-Tetrahydrobenz[c,d]indole, ein Verfahren zu ihrer Herstellung und ihre Verwendung | |
DD231350A5 (de) | Verfahren zur herstellung von 6-phenyl-4,5-dihydro-3(2h)-pyridazinon-verbindungen und ihren salzen | |
DE2811780A1 (de) | Neue triazinverbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
EP0888313B1 (de) | 2,3-benzodiazepinderivate und deren verwendung als ampa-rezeptoren-hemmer | |
DD150466A5 (de) | Verfahren zur herstellung substituierter 3-alkyl-6-phenyl-1,2,4-triazolo[4,3-a]pyridine | |
DE19826841A1 (de) | Arylalkanoylpyridazine | |
DE2718669A1 (de) | 1,2-dihydronaphthalinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
US4117130A (en) | Method for treating anxiety in mammals | |
DE3124699A1 (de) | Neue 2-aryl-3,4-diaza-bicyclo(4.n.0.)alken-(2)-one-(5),verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
EP0090978A2 (de) | Imidazolylphenyl-tetrahydropyridazine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate | |
DE1946315C2 (de) | 4,5-Dihydro-5-oxo-s-triazolo-[1,5-a]-pyrimidin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
DE2527066A1 (de) | 6-hydrazinopyridazine, verfahren zu ihrer herstellung und arzneimittel | |
CH619462A5 (en) | Process for the preparation of novel piperazinylpyrazines | |
DE2150436A1 (de) | Neue organische Verbindungen,ihre Herstellung und ihre Verwendung | |
DE2166752A1 (de) | Pyridazinderivate | |
EP0001108B1 (de) | Neue 1,4-Dihydropyridazine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
DE69028355T2 (de) | 4,5-Dihydro-6H-imidazo[4,5,1-ij]chinolin-6-on-6-oxim-O-sulfonsäurederivate | |
DE2928219A1 (de) | Optisch aktive oder racemische 10-brom-14-oxo-e-homoeburnanderivate, 1-alkyl-9-bromhexahydroindolochinoliziniumderivate, 1-alkyl-1-(2'-alkoxycarbonylaethyl)-9-brom-1,2,3,4,6,7,12,12b-octahydroindolo eckige klammer auf 2,3-a eckige klammer zu chinolizin- bzw. 1-alkyl-1 -(2'-carboxyaethyl)-9-brom-1,2,3,4,6,7, 12,12b-octahydroindolo eckige klammer auf 2,3-a eckige klammer zu chinolizinderivate und 5-bromtryptamin-2-carbonsaeurederivate, verfahren zur herstellung derselben und von optisch aktiven oder racemischen 10-bromvincaminsaeureesterderivaten und optisch aktive oder racemische 10-bromvincaminsaeureesterderivate sowie erstere oder letztere enthaltende arzneimittel | |
DE2242059A1 (de) | 2,4-dihydro-1h-s-triazolo eckige klammer auf 4,3-a eckige klammer zu eckige klammer auf 1,4 eckige klammer zu benzodiazepine und verfahren zu ihrer herstellung | |
DE2807145A1 (de) | Pyrrolochinoxalinone und pyrrolobenzdiazepinone, verfahren zu ihrer herstellung und ihre verwendung | |
DD244556A5 (de) | Verfahren zur herstellung von (-)-1beta-aethyl-1alpha-(hydroxymethyl)-1,2,3,4,6,7,12,12b alpha-octahydro-indolo(2,3-a)chinolisin | |
AT361495B (de) | Vefahren zur herstellung von neuen substi- tuierten 6-phenyl-1,2,4-triazolo(4,3-b) pyridazinen und deren salzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8128 | New person/name/address of the agent |
Representative=s name: SPOTT, G., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 800 |
|
8139 | Disposal/non-payment of the annual fee |